Treatment of COVID-19 Patients at a Medical College Hospital in Bangladesh.
Bangladesh
Coronavirus disease 2019
Therapy
Journal
Euroasian journal of hepato-gastroenterology
ISSN: 2231-5047
Titre abrégé: Euroasian J Hepatogastroenterol
Pays: India
ID NLM: 101577625
Informations de publication
Date de publication:
Historique:
entrez:
4
8
2020
pubmed:
4
8
2020
medline:
4
8
2020
Statut:
ppublish
Résumé
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has induced a sense of panic around the world as the disease is highly contagious and has been spreading in full swing during last 5 months causing millions of COVID-19 patients and hundreds of thousands of deaths. Bangladesh, a country of 170 million people, is not an exception regarding COVID-19; it has reported several thousand COVID-19 patients with several hundred of deaths. This observational study has been planned to assess the scope and limitation of management strategy against COVID-19 patients in a medical college hospital of Bangladesh with available drugs in a real-life situation. All patients in this cohort ( Out of total 33 patients, 1 patient died at day 4 day after admission. Two patients developed severe complications and were referred to tertiary hospital in Dhaka (2 and 3 days after admission), the capital of Bangladesh, where they recovered and were discharged from hospital after being SARS-CoV-2 negative. The rest 30 patients were discharged from the medical college hospital after being negative for SARS-CoV-2 in two subsequent assessments and improvement of their COVID-related symptoms. The average hospital stay of these patients was 14.5 days with a range of 10-24 days. It seems that most of the COVID-19 patients may be adequately managed by standard of care management with drug support. However, early diagnosis and hospitalization with adequate care may be important variables for better survival. These factors may be properly ensured if the patient burden remains at a palatable level in forthcoming days in Bangladesh. Bhuyan MAR, Al Mahtab M, Ashab E,
Sections du résumé
BACKGROUND AND AIM
OBJECTIVE
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has induced a sense of panic around the world as the disease is highly contagious and has been spreading in full swing during last 5 months causing millions of COVID-19 patients and hundreds of thousands of deaths. Bangladesh, a country of 170 million people, is not an exception regarding COVID-19; it has reported several thousand COVID-19 patients with several hundred of deaths. This observational study has been planned to assess the scope and limitation of management strategy against COVID-19 patients in a medical college hospital of Bangladesh with available drugs in a real-life situation.
MATERIALS AND METHODS
METHODS
All patients in this cohort (
RESULTS
RESULTS
Out of total 33 patients, 1 patient died at day 4 day after admission. Two patients developed severe complications and were referred to tertiary hospital in Dhaka (2 and 3 days after admission), the capital of Bangladesh, where they recovered and were discharged from hospital after being SARS-CoV-2 negative. The rest 30 patients were discharged from the medical college hospital after being negative for SARS-CoV-2 in two subsequent assessments and improvement of their COVID-related symptoms. The average hospital stay of these patients was 14.5 days with a range of 10-24 days.
CONCLUSION
CONCLUSIONS
It seems that most of the COVID-19 patients may be adequately managed by standard of care management with drug support. However, early diagnosis and hospitalization with adequate care may be important variables for better survival. These factors may be properly ensured if the patient burden remains at a palatable level in forthcoming days in Bangladesh.
HOW TO CITE THIS ARTICLE
UNASSIGNED
Bhuyan MAR, Al Mahtab M, Ashab E,
Identifiants
pubmed: 32742969
doi: 10.5005/jp-journals-10018-1317
pmc: PMC7376594
doi:
Types de publication
Journal Article
Langues
eng
Pagination
27-30Informations de copyright
Copyright © 2020; Jaypee Brothers Medical Publishers (P) Ltd.
Déclaration de conflit d'intérêts
Source of support: Nil Conflict of interest: None
Références
Infect Genet Evol. 2020 Sep;83:104351
pubmed: 32387564
Microb Pathog. 2020 Aug;145:104209
pubmed: 32311431
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
JAMA Intern Med. 2020 May 1;:
pubmed: 32356871
Br J Haematol. 2020 May;189(3):428-437
pubmed: 32297671
Int J Antimicrob Agents. 2020 Mar;55(3):105924
pubmed: 32081636
J Immunother Cancer. 2018 Jun 15;6(1):56
pubmed: 29907163
N Engl J Med. 2020 Mar 5;382(10):929-936
pubmed: 32004427
N Engl J Med. 2020 Mar 19;382(12):1177-1179
pubmed: 32074444
N Engl J Med. 2020 Mar 5;382(10):970-971
pubmed: 32003551
Travel Med Infect Dis. 2020 May - Jun;35:101738
pubmed: 32387409
Semin Immunopathol. 2017 Jul;39(5):517-528
pubmed: 28555385
J Infect. 2020 Jun;80(6):607-613
pubmed: 32283152
Nat Microbiol. 2020 Apr;5(4):536-544
pubmed: 32123347
Eur J Clin Microbiol Infect Dis. 2020 Jun;39(6):1059-1061
pubmed: 32342252
N Engl J Med. 2020 Mar 26;382(13):1278-1280
pubmed: 32069388
JAMA. 2020 Feb 21;:
pubmed: 32083643